IGF1 and acromegaly: The post-hoc analysis of the PRYMARYS clinical trial (34) examined 90 treatment-naïve acromegaly patients with macroadenomas, the potential predictive factor to SRL response, and found that older age, female sex, and lower IGF-1 levels at baseline were associated with an increased probability of achieving long-term hormonal control.